152 related articles for article (PubMed ID: 37889870)
1. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
2. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
Li M; Liao K; Chen AJ; Cascone T; Shen Y; Lu Q; Shih YT
J Natl Cancer Inst; 2023 Mar; 115(3):295-302. PubMed ID: 36346180
[TBL] [Abstract][Full Text] [Related]
3. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
5. Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer.
Malinowski C; Lei X; Zhao H; Giordano SH; Chavez-MacGregor M
JAMA Oncol; 2022 Jun; 8(6):863-870. PubMed ID: 35389432
[TBL] [Abstract][Full Text] [Related]
6. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
7. Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes.
Kurani SS; Heien HC; Sangaralingham LR; Inselman JW; Shah ND; Golden SH; McCoy RG
JAMA Netw Open; 2022 Jan; 5(1):e2143597. PubMed ID: 35040969
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.
Howell AV; Gebregziabher M; Thiers BH; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2021 Apr; 12(3):394-401. PubMed ID: 33132048
[TBL] [Abstract][Full Text] [Related]
9. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2022 Sep; 13(7):1003-1010. PubMed ID: 35660090
[TBL] [Abstract][Full Text] [Related]
10. Exit Rates of Accountable Care Organizations That Serve High Proportions of Beneficiaries of Racial and Ethnic Minority Groups.
Lin SC; Maddox KEJ; Ryan AM; Moloci N; Shay A; Hollingsworth JM
JAMA Health Forum; 2022 Sep; 3(9):e223398. PubMed ID: 36218951
[TBL] [Abstract][Full Text] [Related]
11. Medicare Eligibility and Racial and Ethnic Disparities in Operative Fixation for Distal Radius Fracture.
Benítez TM; Ouyang Z; Khouri AN; Fahmy JN; Wang L; Chung KC
JAMA Netw Open; 2023 Dec; 6(12):e2349621. PubMed ID: 38153736
[TBL] [Abstract][Full Text] [Related]
12. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
13. Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes.
Rodriguez-Gutierrez R; Herrin J; Lipska KJ; Montori VM; Shah ND; McCoy RG
JAMA Netw Open; 2019 Oct; 2(10):e1913249. PubMed ID: 31603490
[TBL] [Abstract][Full Text] [Related]
14. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
15. Differences in presentation, treatment, and outcomes among minority head and neck cancer patient groups in Los Angeles County.
Lin ME; Castellanos CX; Bagrodia N; West JD; Kokot NC
Am J Otolaryngol; 2024; 45(1):104031. PubMed ID: 37639986
[TBL] [Abstract][Full Text] [Related]
16. Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups.
Taylor DB; Osazuwa-Peters OL; Okafor SI; Boakye EA; Kuziez D; Perera C; Simpson MC; Barnes JM; Bulbul MG; Cannon TY; Watts TL; Megwalu UC; Varvares MA; Osazuwa-Peters N
JAMA Otolaryngol Head Neck Surg; 2022 Feb; 148(2):119-127. PubMed ID: 34940784
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
18. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
19. Racial and Ethnic Disparities in Hospitalization Outcomes Among Medicare Beneficiaries During the COVID-19 Pandemic.
Song Z; Zhang X; Patterson LJ; Barnes CL; Haas DA
JAMA Health Forum; 2021 Dec; 2(12):e214223. PubMed ID: 35977303
[TBL] [Abstract][Full Text] [Related]
20. Associations of Race/Ethnicity and Food Insecurity With COVID-19 Infection Rates Across US Counties.
Kimani ME; Sarr M; Cuffee Y; Liu C; Webster NS
JAMA Netw Open; 2021 Jun; 4(6):e2112852. PubMed ID: 34100936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
